Anavex Life Sciences Corp (AVXL)

[makemydaze]

The abstract of Timo Grimmer's presentation at Alz Europe-

Abstract Details
Title: Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine
Authors: Christopher Missling, United States; Timo Grimmer, Germany; Juan-Carlos Lopez-Talavera, United States; William R Chezem, United States; Kun Jin, United States; Nell Rebowe, United States; Marwan N Sabbagh, United States
Session: P44.Treatment & Medical management - 4 Modules, 08/10/2025, 10:30 - 11:45
Time: 11:15 - 11:30
Currently no new convenient patient-centric oral disease-modifying treatments are approved for Alzheimer’s disease (AD) without the requirement of complex logistical resources and added personnel for drug administration and expensive safety monitoring.

Recently published in JPAD, blarcamesine demonstrated in a placebo-controlled, 48-week Phase IIb/III trial (ANAVEX2-73-AD-004) promising clinical results (numerically superior to injectable infusion mAbs) with meaningful improvements on top of standard of care (donepezil, etc.) with slowed clinical progression by 36.3% (all patients) and 49.8% (prespecified patient group ~70% of population) at 48 weeks as measured by the primary endpoint ADAS-Cog13 and also on predesignated biomarkers. Blarcamesine demonstrated a strong safety profile with no neuroimaging-related side effects. There were no deaths related to the study drug. Study publication (link).

The trial inclusion requirements were readily manageable for both the patients and the families with no mandatory invasive assessments. The emphasis was on the National Institute on Aging (NIA)–AA criteria for diagnosis of early-stage mild-dementia due to AD. The same accommodating procedures would be followed upon potential market approval.

The advantage for the patient would be being helped timely without delays and constrains by cumbersome and limiting inconvenient complex diagnostics procedures allowing for quicker time-sensitive access with continued focus on the individual patient.

The advantage for the family would be less caregiver stress, and likely less financial strain with no need to arrange for constant transportation and no impact on own work schedule.

The advantage for the physician would be no logistical barriers to treatment with no need to arrange or schedule complex, invasive PET scans, lumbar puncture (spinal tap) or repeated MRIs.

In summary, the impact on daily life is favorable with oral Alzheimer's treatment blarcamesine. It maintains independence of loved ones longer, safely, giving better outcomes, while allowing efficiency and convenience for patients and families.

https://www.alzheimer-europe.org/conferences/2025-bologna/detailed-programme?language_content_entity=en